The elevated neutrophil-to-lymphocyte ratio in the TME during neoadjuvant chemotherapy could impair its anti-tumor efficacy due to upregulated neutrophil-CAFs-tumor cell IL-1β/IL-6/STAT-3 signaling, showing a poor/absent response [35]. The gene discussed is STAT3; the disease is neoplasm.